MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

Inclusion Criteria: * Histologically or cytologically confirmed metastatic clear cell renal cell cancer; * At least one lesion that can be accurately measured in at least one dimension; * Patients must not have been treated with prior anti-timor kinase inhibitors or VEGF pathway inhibitors; * Age 18 and older; * ECOG performance status 0-2; * Blood pressure higher than 140/90 on 2 separate occasions not more than 6 weeks prior to enrollment and not less than 24 hours apart; * Normal organ function: total bilirubin less than upper limit of normal, AST less than 2.5 X upper limit of normal, creatinine less than 2.8 mg/dl; * Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation; * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Chemotherapy or radiotherapy within 4 weeks prior to entering the study; * Any other investigational agents; * Known brain metastases; * Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; * Pregnancy.